Categories
Entertainment

Benzino Tells Coi Leray That Latto ‘Admires’ Her

Coi Leray and her father, Benzino, are sharing their reactions after Latto seemingly dissed the latter in her latest feature verse. As The Shade Room previously reported, Latto attempted to mend her relationship with Coi Leray while on stage at Coachella in April. At the time, Leray caught offense to Latto previously rapping that she was “smoking” b****s “big as Coi Leray.”

However, Leray appeared to dodge Latto’s olive branch and recently released a single where she rapped that she rolled up “Latto out the bag,” as per TMZ.

RELATED: WATCH: Latto Reacts To Coi Leray’s Body-Shaming Accusations While Performing At Coachella

More Details Regarding Latto’s Feature Verse On ‘Peaches & Eggplants’

The remix to rapper Young Nudy’s single, “Peaches & Eggplants,” was released on Friday. The single featured Latto and fellow female rapper Sexyy Red.

After the single’s release, Latto took to Instagram to share a carousel of photos and videos in promotion of the single’s music video. Amid the carousel, the rapper included a video snippet where she referred to Benzino alongside a picture of him.

“Give me that neck like Benzino, give me that neck like, ‘where it go?’” Latto rapped.

Coi Leray Responds To Latto’s Mention Of Her Father As Latto Further Explains The Lyric

Afterward, Coi Leray seemingly responded to Latto’s mention of her father, Benzino.

“Someone find me a pick of Karen,” the 26-year-old wrote on X.

However, Leray’s tweet didn’t appear to faze Latto as the rapper then hopped on Instagram Live to further explain her lyrics mentioning Benzino.

Some of y’all needed a breakdown… Let me break it down for the people that’s not fast,” the rapper explained. “I said, ‘Give me that neck like Benzino.’ That mean, if I say, ‘Give me that,’ that mean it’s took, right? That mean it’s gone, right?”

The rapper went on to address fans who thought the lyric made “no sense” by encouraging them to “keep up.”

Coi Leray Shares Her Text Exchange With Father Benzino As They React To Latto’s Verse

Over the weekend, Leray returned to X to share a screenshot of a text exchange with her father, Benzino. In the messages, Benzino told Leray that Latto “admires her.” Additionally, he said, “They all do,” seemingly referring to Leray’s fellow female rappers.

In the messages, Benzino even poked at his “most famous neck on earth.” Meanwhile, Leray remarked on how “these lil stupid situations” bring them “together.”

Roommates, what do you think of this ongoing tiff between Latto and Coi Leray?

RELATED: Coi Leray Accuses Latto Of Body-Shaming Her In ‘Put It On Da Floor’: ‘Y’all Wanna Have Rap Beef So Bad’
Categories
Technology

Most cancers affected person digital twins and AI tapped to turbocharge oncology

Dell and University of Limerick (UL) in Ireland have teamed up to advance cancer research using AI.

Specifically, the tech giant will be working with UL’s Digital Cancer Research Centre to help doctors provide more efficient cancer care for patients suffering from B-cell lymphoma. This covers the entire spectrum of care, from speeding up diagnosis to improving treatment and long-term outcomes.

To achieve this, Dell has developed an AI platform, powered by the company’s latest storage arrays and PowerEdge servers. The platform is now part of the Centre’s multicloud ecosystem, and is able to produce digital twins of patients.

The technology is expected to facilitate the researchers’ work in multiple ways. They’ll be able to accelerate biomarker testing for cancer, gain further insights on appropriate treatments, and develop personalised therapies based on the individual’s tumour characteristics.

The Financial Times’ award-winning, flagship digital event, The Global Boardroom, is back!

Join the FT, in partnership with TNW, 8-10 November, as we explore the most effective strategies for growth in the midst of geopolitical, economic and technological disruption →

By further understanding the pathogenesis of these malignancies, the researchers will also have the opportunity to devise novel therapeutic approaches. One such example is the role collagen inside the tumour’s “micro-environment” can play in spreading cancerous cells to the body and the central nervous system.

“Through our partnership with the Dell Technologies team, we will be able to advance our knowledge of how cells go wrong during cancer development and find new ways to diagnose and treat cancer patients,” said Paul Murray, Professor of Molecular Pathology at UL and Director of the Digital Pathology Unit at the Digital Cancer Research Centre.

According to Catherine Doyle, Managing Director of Dell in Ireland, the partnership is taking cancer clinical research “to a new level” with the potential to “benefit patients and healthcare professionals globally.”

Categories
Health

Ozempic, Wegovy might curb ingesting, smoking: What we all know

An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. 

Jaap Arriens | Nurphoto | Getty Images

Heather Le Biller shed 9 pounds within the first week of taking Novo Nordisk‘s blockbuster diabetes drug Ozempic – and then even more as she continued treatment. 

Le Biller, a flight attendant who lives in France, noticed her appetite quiet down while taking the weekly injection. But so did her cravings for wine, a drink she called “almost customary to pair with every dinner” in France. 

“When I was on Ozempic, it made me not want that as much anymore,” Le Biller told CNBC. “I could have a few sips of wine and just be satisfied and move on. I didn’t need multiple glasses a night, so it definitely seems to help with that.” 

Le Biller is among several patients who took diabetes and weight loss drugs and also noticed an effect on their cravings for alcohol, nicotine, opioids or even some compulsive behaviors, such as online shopping and gambling.

Those drugs – including Ozempic and its weight loss counterpart from Novo Nordisk, Wegovy – are called GLP-1 agonists, which mimic a hormone produced in the gut to suppress a person’s appetite. 

These anecdotal reports add to the growing list of potential benefits of GLP-1s beyond shedding unwanted pounds. Dramatic weight loss is the primary reason why those drugs have skyrocketed in popularity in the U.S., despite the fact that they can cost around $1,000 a month and some health insurers have stopped covering them altogether. 

“We’re prescribing these drugs and seeing this effect as a secondary benefit in patients. One of my patients even said they’re not doing as much online shopping, which is helping their wallet,” said Dr. Angela Fitch, an obesity medicine physician and president of the Obesity Medicine Association. That group is the largest organization of physicians, nurse practitioners and other health-care providers dedicated to treating obesity. 

A customer drinks a glass of wine at the It’s Italian Cucina restaurant on April 05, 2023 in Austin, Texas. A new analysis of more than 40 years of accumulated research has found that moderate drinking has no health benefits. 

Brandon Bell | Getty Images

This striking effect of GLP-1s isn’t a new idea. Several studies have demonstrated that certain GLP-1s curb alcohol intake in rodents and monkeys. 

More research needs to be done, particularly on humans, to prove that the drugs have that effect. That means it could take years before the Food and Drug Administration and other regulators worldwide approve drugs like Ozempic and Wegovy as addiction treatments. 

Novo Nordisk told CNBC in a statement that they aren’t pursuing that research.

“Pharma has this general lack of interest in investing in the addiction field” due to a perfect storm of factors, including the high stigma around addiction disorders among doctors, physicians and even patients, according to Dr. Lorenzo Leggio, clinical director of the National Institute on Drug Abuse, or NIDA.

Leggio and other scientists are working to fill the gap – and have already made strides toward confirming the potential of GLP-1s as addiction treatments.

What do we know so far?

Scientists have published nearly a dozen studies showing how GLP-1s stop binge drinking in rats and mice, reduce their desire for alcohol, prevent relapse in addicted animals and decrease alcohol consumption overall. 

Earlier studies have examined older, less potent GLP-1s such as exenatide, a drug approved for diabetes under the names Byetta and Bydureon. 

But more recent studies on semaglutide – the generic name for Ozempic and Wegovy – and another drug from Eli Lilly called dulaglutide “are the most promising” because they reduced alcohol intake in animals by 60% to 80%, according to pharmacologist Elisabet Jerlhag. 

Studies have also shown that rats that stop taking dulaglutide, which is approved for diabetes under the name Trulicity, “take weeks before they start drinking again,” she said.

Jerlhag and her colleagues at the University of Gothenburg in Sweden have studied the effect of GLP-1s on addictive behaviors for more than a decade. 

Boxes of the drug trulicity, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo, Utah, January 9, 2020.

George Frey | Reuters

Other studies on animals have also found that GLP-1 drugs reduce the consumption of nicotine, cocaine, heroin and amphetamines. 

Few studies have been done on humans, but six clinical trials are now underway investigating how semaglutide may alter people’s drinking and smoking habits. 

The reason behind this anti-addiction effect of GLP-1s is that those drugs also affect the brain, not just the gut, according to NIDA’s Leggio. 

“The mechanism in the brain that regulates overeating is important in regulating addictive behaviors as well,” Leggio told CNBC. “There is a clear shared overlap. So it’s possible that the medications may help people with addiction by acting on that specific mechanism.”

GLP-1s specifically decrease the amount of dopamine the brain releases after people indulge in behaviors like drinking, smoking or even eating a sweet dessert, according to Dr. Steven Batash, a gastroenterologist who provides nonsurgical weight loss procedures in Queens, New York. 

Batash said dopamine is a neurotransmitter that “reinforces the pleasure” of doing those activities. When GLP-1s take away that pleasure, they also eliminate the motivation to do those activities. 

What needs more research?

Still, NIDA’s Leggio advises against using GLP-1s off-label to reduce addictive behaviors, “simply because there’s not enough evidence in humans that they work.” 

“The animal studies are very promising and what people are reporting is very, very important, but as a scientist, I will also tell you that that’s not enough,” he told CNBC. 

Leggio said scientists need to conduct more double-blind, randomized, placebo-controlled studies on humans – or trials where both participants and researchers don’t know who is getting randomly selected to receive a placebo or an actual drug. Those types of studies are “the gold standard” for proving whether a treatment achieves a certain effect or not, he added

But even if those trials confirm that GLP-1s can reduce addictive behaviors in humans, “it will most likely work for some patients and not others,” according to Leggio. 

“We already know, as a matter of fact, that these medications and any drug overall do not work for everybody,” he said. 

The Good Brigade | Digitalvision | Getty Images

For example, the only clinical study in this area investigated whether exenatide could treat alcohol use disorder in people, as compared with cognitive behavioral therapy.

But a subgroup analysis of that 2022 study found that exenatide reduced drinking in a subgroup of participants who had obesity, while the drug actually increased drinking in people who didn’t. 

The reason may be that “leaner patients” treated with exenatide experienced a larger decrease in blood sugar, which might be associated with increased cravings for alcohol, the researchers wrote in the study.

But even that hypothesis needs to be confirmed with further research. 

It’s also unclear how long the anti-addiction effect of GLP-1s will last. That’s already one complaint patients have when it comes to weight loss: People who lose weight after taking Ozempic or Wegovy tend to gain most of it – or even more – back within a few years. 

“It’s possible that some people will relapse and go back to heavy drinking if they stopped taking the medication,” Leggio said. He added that some patients will need constant treatment because addiction is a chronic disease. 

However, Leggio said there’s “nothing wrong” with a patient seeking GLP-1s to treat diabetes or obesity, in addition to an addiction disorder. 

“If you want to see whether Ozempic will help you better control the sugar in your blood but also help you with your drinking, that’s wonderful. Killing two birds with one stone,” Leggio said. “But if the only reason you want to take the drug is because of your alcohol or smoking, then you should wait for more evidence.” 

It may take years, but scientists and other health experts hope that a new class of treatments for alcohol use disorder, smoking and other addictive behaviors is on the horizon. 

“It may be that three, four or five years from now, you and I are going to say that GLP-1 agonists are wonderful for treating mild diabetes, wonderful for weight loss, and perhaps we will also say that they are wonderful for curbing addictive behaviors,” Batash told CNBC.

But even if GLP-1s get approved to treat addiction, it’s unclear how many people would take them. Uptake of existing medications for addiction is already low.

About 14 million American adults had alcohol use disorder – a disease associated with uncontrolled drinking – in the past year as of 2019. But only 1.6% used any of the three FDA-approved drugs for the condition. 

Categories
Science

The Woke Transformation of the Australian Academy of Science • Watts Up With That?

Peter Ridd recently wrote an excellent article for SPECTATOR AUSTRALIA

A Shift from Science to Sentiment

In the realm of scientific research and discovery, the Australian Academy of Science (AAS) once stood as a beacon of rigorous inquiry and evidence-based conclusions. However, a recent article from the Spectator Australia paints a rather different picture of the institution, suggesting it has veered off the path of objective science and into the murky waters of woke ideology.

“The Australian Academy of Science (AAS) recently released a report Reef Futures Roundtable, which is ostensibly about the doomed Great Barrier Reef. However, the report only demonstrates that the AAS, Australia’s peak science body, has become not just unscientific, but anti-scientific.”

Selective Reporting and Omissions

The AAS report on the Great Barrier Reef, rather than presenting a comprehensive and balanced view, seems to cherry-pick data to fit a predetermined narrative. The glaring omission of UNESCO’s declaration that the reef is not endangered and the latest statistics showing the reef at peak coral levels raises eyebrows.

“The AAS report predictably concluded that the Great Barrier Reef could already be ‘irreversibly’ damaged. The fact that UNESCO has just declared it not endangered did not rate a mention, and neither did the latest two years of statistics showing the reef is at record high coral levels.”

A Lack of Quantitative Analysis

For an institution that once prided itself on rigorous scientific methodology, the AAS report’s lack of quantitative data is both surprising and concerning. The report’s recommendations, such as ‘solar radiation management’ and ‘rubble stabilisation’, seem to be based more on wishful thinking than practical feasibility.

“The problem with this completely unanalytical approach is seen in the ‘interventions’ it recommends to fix the reef. Their impracticality is breathtaking.”

The Woke Overtones

Perhaps the most striking aspect of the AAS report is its overtly woke tone. The emphasis on gender identification and Indigenous representation, while important in certain contexts, seems misplaced in a scientific report. The prioritization of identity politics over hard data is a clear departure from the AAS’s traditional approach.

“The unscientific nature of the AAS report is largely a result of its anti-scientific approach. The report is actually a parody of wokeness and romantic mythology.”

The Real Threat: Abandonment of Scientific Rigor

The Spectator’s article highlights a concerning trend in modern scientific institutions: the gradual shift from evidence-based research to ideologically driven narratives. The AAS’s focus on gender and race statistics, at the expense of genuine scientific data, is a testament to this shift.

“The AAS ascribes such importance to facts and figures on gender and race, but not to scientific facts. This demonstrates it is anti-science.”

In Conclusion

The Australian Academy of Science, once a revered institution, appears to be losing its way. The prioritization of woke ideology over rigorous scientific inquiry is not only a disservice to the scientific community but also to the general public that relies on such institutions for unbiased, evidence-based information. The Spectator’s article serves as a timely reminder of the importance of maintaining scientific integrity and the dangers of allowing ideology to cloud objective research.

“I have been saying for some time that many of our science institutions have become totally untrustworthy. By its wilful abandonment of quantitative analysis, the AAS has destroyed its reputation as a source of useful scientific advice. The media loves a bad news story – they should focus on what has happened to a once-esteemed organisation.

“The Australian Academy of Science is now a joke.”

Read the full article here.

Like this:

Like Loading…

Categories
Sport

Djokovic vs. Medvedev – Who will win the US Open males’s title?

Two years ago, Novak Djokovic and Daniil Medvedev met in the US Open final — and Medvedev took the title. It’s his only Grand Slam to date — will he win another one on Sunday? Or will Djokovic capture his 24th major, setting the overall record of the Open era?

Who will win? We asked our experts:

What can Djokovic do to defeat Medvedev?

Alexandra Stevenson: Djokovic just has to be Djokovic. If he brings a high percentage of first serves and a solid baseline game, he beats Medvedev with his agility and over-the-top mental focus. Djokovic’s team will come up with every tactic to beat Medvedev — take a look at previous matchups.

Grand Slam No. 24 is for sure in Djokovic’s head, but this time, he is treating the match with a focus on one thing: Playing his game. His movement, twists and turns should be studied by junior players. His defense is clearly the best in the field.

With the NFL and college football starting, it’s timely to compare Djokovic to a quarterback. He knows the rhythm of the court with his aggressive groundstrokes. Think scrambling Patrick Mahomes. And Djokovic is using the net — something we’ve seen more of in the men’s game in 2023 — a throwback to the Pete Sampras era.

Rennae Stubbs: Use his vast experience in these moments.

Alyssa Roenigk: Djokovic didn’t get the Wimbledon rematch tennis fans wanted, but another shot at Medvedev in the US Open final isn’t a bad consolation. Two years ago, Medvedev stopped Djokovic’s run at the calendar-year Grand Slam. In that match, Djokovic converted only 17% of his break-point opportunities and struggled to return Medvedev’s serve.

Here, his return game has been stellar. He held big-serving Ben Shelton to just five aces and broke him five times in their semifinal, and he’ll need to do the same on Sunday. Djokovic knows he might not have many more chances to add to his 23 major titles.

D’Arcy Maine: After his win Friday over Shelton, Djokovic said he had allowed himself to get “overwhelmed with the occasion and the opportunity” during the 2021 US Open with both the calendar-year Grand Slam and a then-record-breaking 21st major title on the line. Now playing the same opponent that defeated him in that very final, and with another record up for grabs, Djokovic will need to do everything he can to remain focused simply on the match and nothing else.

Having beaten Medvedev in four of their five meetings since that 2021 final, Djokovic knows he has the game and the tactics to beat him, so it might just come down to his mental toughness when the stakes are highest.

Bill Connelly: Conjure the old Djokovic return. His return prowess has slipped ever so slightly in recent years — after winning 42-43% of his return points basically every year through 2021, he’s been at 41% over the past couple of years. That seems like a tiny difference, but tennis has tiny margins. And his matches with Medvedev have been almost entirely driven by how well Medvedev is winning his serve. When Djokovic was dominating the early stages of this rivalry, he was routinely winning over 40% of return points against Medvedev. But he won only 29% in their 2021 US Open meeting, and he won only 34% in his loss to Medvedev in Dubai this year. Medvedev served brilliantly in his win over Carlos Alcaraz in Friday’s semifinal. Djokovic will have to counter that.

Medvedev is looking for his second Grand Slam title. Frey/TPN/Getty Images

What can Medvedev do to defeat Djokovic?

Stevenson: Medvedev has to bring his first serve, like he did against Alcaraz. And continue to hit big from the baseline. He has an uncanny ability to change things up — and win the point. However, it’s unsettling to see him return serve so far, far, far behind the baseline.

Overall, he’s borrowed a look from the women’s game: consistency. A quiet warrior in this Grand Slam. His mental focus is solid as a rock, and he has simplicity in his game.

Stubbs: He has to serve at his best, try and get free points in his serve and then try his best to take his chances in the return games.

Roenigk: In 36 Grand Slam finals over 16 years (23 of which Djokovic won), only six men managed to beat Djokovic, and only three — Rafael Nadal, Andy Murray and Stan Wawrinka — did it more than once. Sunday will be no easy lift for Medvedev. Against Alcaraz, the Russian said he played “12 out of 10” and “better than myself” to beat the young Spaniard. He will need to raise that level to 13 against Djokovic, who hasn’t dropped a set since the third round.

Maine: Medvedev thrives in the spoiler role, and feeding off of the energy of the crowd. He’s been in this exact position before and he knows what he needs to do. And he even has a more recent match to turn to when crafting a game-plan for Sunday. During their last meeting in Dubai in March, Medvedev ended Djokovic’s perfect start to the season with his combination of stellar movement, powerful ball striking, minimal errors and by capitalizing on Djokovic’s mistakes. If he can replicate that strategy, and stay as focused and composed as he has throughout the tournament, he has a real chance of winning his second US Open title.

Connelly: Be impenetrable. When he beat Djokovic in Dubai in February, Medvedev’s serve was huge and accurate, and perhaps more importantly, he made just seven unforced errors in 124 points (6% of points). When he beat Alcaraz on Friday night, he made 32 errors in 262 (12%). At his best, Medvedev plays the human-backboard role to perfection, parking far behind the baseline but returning everything his opponent throws at him with extreme depth and pace. He completely defines the match. He’s painfully annoying for his opponent, in other words. Djokovic said the moment got to him when he lost to Medvedev at the 2021 US Open, but Medvedev gave him absolutely nothing, too.

Djokovic is aiming for a record 24th Grand Slam title, which would be the most of any player in the Open era. Photo by Frey/TPN/Getty Images

Who will win?

Stevenson: I’ve had Djokovic winning from the beginning. He’ll get his No. 24, if the Djokovic tactical game is firing big on Arthur Ashe. Djokovic!

Stubbs: Medvedev. I think he feels forgotten this year and his best surface is this one in NYC. I also think he’s been tested throughout this tournament and he knows he can best Djokovic in this match.

Roenigk: Djokovic hasn’t lost back-to-back Grand Slam finals since a stretch between 2013 and 2014 when he finished runner-up at Wimbledon (Murray), the US Open (Nadal) and the French Open (Nadal). He is a different player a decade later and, unlike 2021, will be ready to face the best version of Medvedev on Sunday.

Maine: Having witnessed in person Medvedev’s absolute dismantling of Djokovic in that 2021 US Open final and spoiling his bid for the calendar-year Slam, I feel safe in saying: anything is possible on Sunday. But Djokovic, who said he didn’t know how many more Grand Slam finals he would get to play in when talking to the media Friday, will do everything in his power to not let this opportunity for major title No. 24 slip away. Djokovic in four.

Connelly: It can feel at times that Alcaraz and Djokovic have distanced themselves a bit, but Friday night was a reminder that when Medvedev is at his best, he is still more than capable of dictating matches and playing like the best player in the world. I’m picking Djokovic, because when you pick Djokovic you’re almost always right. But Medvedev was so sharp on Friday, I’m going to say it takes Djokovic a full five sets to get this one done.

Categories
Entertainment

These 14 Leggings Are Squat-Proof Based on Reviewers

If you’re looking for high-quality, top-rated leggings, this pair has 63,500+ 5-star Amazon reviews. They’re available in standard and plus sizes with options for full-length, capri-length, and pockets. Choose from 25 colors.

A shopper said, “These leggings have great stretch, stay in place and are amazingly soft. I’m a large grandma that likes to be comfortable and I bought 2 more colors!”

Another raved, “Most comfortable, soft, & flattering leggings I’ve ever had. The pockets are the perfect size and in the ideal spot, the high waist has a wide band that is just the right size and comes up exactly where it should to be both comfortable and flattering. They stay up where they should, even over large hips, so you’re not having to constantly pull them up all the time.”

Categories
Technology

EU has ‘no probability’ of chip independence. Nor does anyone else

Our world runs on semiconductors. The silicon slivers are the brains of our phones, computers, cars, data centres, and stock markets. They’re also the digital backbone of modern militaries. 

Some of the first chips ever made were used in missile guidance systems. Today, they power countless military devices, from fighter jets and howitzers to radios and radar.

In the Russia-Ukraine war, semiconductors enable HIMARS rocket launchers, Javelin anti-tank missiles, and the Starlink communications satellites. They’re also integral to the arms race underway in East Asia, where territorial disputes in the East and South China Seas risk spiralling into a major conflict. The rise of artificial intelligence adds another dimension to the hostilities: there’s now a dearth of AI chips.

In the EU, the shortages and frictions led the bloc to introduce the €43bn Chips Act. The investment package aims to boost local production and reduce international dependencies. Experts, however, have downplayed any prospects of sovereignty.

Catch up on our conference talks

Watch videos of our past talks for free with TNW All Access →

According to Chris Miller, the author of Chip War, the EU has “no chance” of semiconductor independence — and neither does anybody else.

The problem, he argues, is that the supply chain is simply too globalised and interconnected.

“Independence is hopeless,” Miller, an economic historian, told TNW at the IFA Berlin tech show. “It’s not going to happen — nor do I think Europe is pushing for it.”

A divided industry

In Chip War, Miller recounts the decades-long battle to control semiconductors, which today centres on the rivalry between the US and China. Tensions between the nations have torn the chip world into two.

As the fractures widen, Beijing is trying to nurture a domestic semiconductor ecosystem. It’s currently the world’s largest importer of the devices, spending more money importing them than it does on oil.

Miller is currently a history professor at Tufts University and a visiting fellow at the American Enterprise Institute. Credit: Chris Miller

To constrain China’s ambitions, Washington has imposed sweeping export controls on chip tech. In 2022, the Biden administration imposed its toughest sanctions yet. Under the new rules, the White House could block not only sales of chips made in the US, but also chips that use American components or software.

The move has disrupted China’s trade with Taiwan, which produces over 60% of the world’s semiconductors — and over 90% of the most advanced ones.

Sanctions have also created problems for Beijing in the EU, which has its own chip powerhouse: ASML.

The Dutch company is the world’s leading manufacturer of high-end chipmaking equipment. Without its gear, Chinese firms will have to overcome another obstacle to produce advanced chips.

That outcome could soon become a reality.

Europe’s chip future

Amid pressure from the US, the Netherlands began blocking exports of advanced chip manufacturing equipment on September 1. Analysts suspect the restrictions specifically target ASML

The move has sparked fears that China will impose retaliatory restrictions. Miller, however, expects Beijing to proceed with caution. He notes that retaliation could backfire.

“China could cause disruptions in supply chains, but they could be just as impacted by the disruptions as the West is,” he said.

Nonetheless, the discord has amplified the calls for autonomy. Publically, the EU is pursuing a policy of “de-risking” rather than “decoupling” from China, but the geopolitical rifts have exposed the need for self-sufficiency. In response, the EU has made plans to produce 20% of the world’s semiconductors — double its current share — by 2030.

It’s a target that Miller believes is “possible,” but only with strong support from the member states and companies.

A precedent for this approach has been set this year in Germany. After offers of enormous subsidies, both Intel and Taiwan’s TSMC have pledged to build chip factories in the country.

Ultimately, semiconductor independence may be impossible — but the EU does already have unique strengths. In machine tools and power semiconductors, for instance, the bloc is home to some of the world leaders.

“I think Europe should keep focusing on what it’s historically been very good at, which is investing in R&D-intensive manufacturing industries,” said Miller.

“The goal is to have profitable chip companies with technological leadership positions — and Europe has that.”

Categories
Health

Meta’s VR expertise helps to coach surgeons and deal with sufferers

Meta CEO Mark Zuckerberg demonstrates an Oculus Rift virtual reality (VR) headset and Oculus Touch controllers during the Oculus Connect 3 event in San Jose, California, U.S., on Thursday, Oct. 6, 2016.

David Paul Morris | Bloomberg | Getty Images

Just days before assisting in his first major shoulder-replacement surgery last year, Dr. Jake Shine strapped on a virtual reality headset and got to work.

As a third-year orthopedics resident at Kettering Health Dayton in Ohio, Shine was standing in the medical center’s designated VR lab with his attending physician, who would oversee the procedure. 

Both doctors were wearing Meta Quest 2 headsets as they walked through a 3D simulation of the surgery. The procedure, called a reverse total shoulder arthroplasty, can last around two hours and requires surgeons to carefully navigate around neurovascular structures and the lungs.

After the mock procedure, Shine took his headset home to practice. He did so roughly twice a day before the surgery.

“You can really fine-tune and learn what to do, but also what definitely not to do, with zero risk to the patient,” Shine told CNBC in an interview. 

Ultimately, there were no complications in the procedure and the patient made a full recovery, he said. 

“Anecdotally, I think it went smoother and quicker than it would have,” Shine said, than if the attending physician “was having to walk me through every step in the case the same way that he did in the VR.” 

While consumer VR remains a niche product and a massive money-burning venture for Meta CEO Mark Zuckerberg, the technology is proving to be valuable in certain corners of health care. Kettering Health Dayton is one of dozens of health systems in the U.S. working with emerging technologies like VR as one tool for helping doctors to train on and treat patients.

The broad category of “extended reality” includes fully immersive VR headsets like the Quest 2, and augmented reality (AR) devices, where the user can see a digital overlay on top of real-world surroundings.

Whether the nascent technology can ever be cost-effective across the medical industry is very much an open question, but early tests are showing the potential utility of VR in helping to improve health outcomes.

Meta, then known as Facebook, entered the market with the purchase of Oculus in 2014. Three years later, the company introduced its first stand-alone headset. In 2021, Facebook rebranded as Meta, and Zuckerberg committed to spending billions, betting the metaverse would be “the next chapter for the internet.” Since the beginning of last year, Meta’s Reality Labs unit, which develops the company’s VR and AR, has lost over $21 billion. 

Apple is preparing to enter the VR market, going after the higher-end user with the $3,500 Vision Pro that’s expected to debut early next year. Meta is slated to release the Meta Quest 3 as soon as next month.

An Apple spokesperson didn’t provide a comment on potential uses in health care and directed CNBC to an announcement in June regarding Vision Pro’s software developer kit. In that announcement, Jan Herzhoff, Elsevier Health’s president, is quoted as saying that her company’s Complete HeartX mixed reality offeringwill help prepare medical students for clinical practice by using hyper-realistic 3D models and animations that help them understand and visualize medical issues, such as ventricular fibrillation, and how to apply their knowledge with patients.”

Meta Quest 3 VR headset.

Meta

Extended reality as treatment for patients

To date, one of the primary applications of VR in health care has been targeted at pain treatment.

“It’s very hard to keep track of pain when you’re in a fantastical cyberdelic world,” said Dr. Brennan Spiegel, director of health services research at Cedars-Sinai in Los Angeles.

Spiegel said that when someone is injured, there is both a physical and an emotional component to their pain. Those signals are sent to two different parts of the brain, and VR can serve to tamp down the signals in both regions.

“It’s training people how to modify their spotlight of attention so they can swing it away from the painful experiences,” Spiegel said. “Not just the physical, but the emotional experiences.” 

Spiegel said Cedars-Sinai is preparing to launch a virtual platform to help people with gastrointestinal issues like Crohn’s disease, celiac disease or acid reflux, as well as others for anxiety, addiction and perimenopausal health.    

The technology has also attracted the attention of the U.S. Department of Veterans Affairs, which is using extended reality at more than 160 facilities to help patients with pain management, behavioral therapy and both physical and cognitive rehabilitation. 

Caitlin Rawlins, the immersive program manager at the VA, said there are currently more than 40 separate use cases for the technology across the agency’s different sites. The VA first introduced extended reality in a limited capacity around 2015, and has found more opportunities to put it to use as the technology has improved. 

“I’ve seen it change a whole lot,” Rawlins told CNBC in an interview. “The first virtual reality headset that I used was this big clunky headset that had all these wires it had to be connected to a laptop to function.”

Rawlins said what drew her to extended reality was seeing the immediate response from patients. She recalled the first time she watched a patient use VR. He was a man in his 80s who had just undergone knee replacement surgery. The pain was so severe that opioids didn’t help, Rawlins said.

After mere minutes in VR, he told Rawlins he couldn’t feel the pain in his leg anymore. 

Just using that for a simple 30-minute session can mean the difference between excruciating pain, unable to do the exercises and the ambulation that they need to, to actually get up and move and get ready to go home,” she said.

Rawlins described another patient as a “surly” wheelchair-bound Army veteran who was experiencing some cognitive decline. The VA had the patient try VR to see if it could lessen the need for antipsychotic medications. 

With the headset on, Rawlins had the patient navigate through a virtual nature scene, walking through the woods, climbing rocks and interacting with birds and deer. Rawlins said the patient was smiling and laughing and was transformed into a “completely different person.”

“To see a patient who has been wheelchair-bound for like 15 years getting to walk through the woods and interact with animals again, it was a pretty powerful moment,” Rawlins said. “Those are the sort of experiences that we keep seeing over and over and over again.”

Both Spiegel and Rawlins said their organizations are hardware agnostic, meaning they can use headsets made by Meta, Apple or any other company as long as they can support the right software.

Spiegel said there’s “potentially millions and millions of people who might be willing to actually buy a headset” but who see them as a gaming and entertainment devices and have no idea about the health applications.

Meta has loosely identified health care as a target market. The company has released case studies and promoted short videos depicting futuristic surgeons in training.

However, it doesn’t appear to be as much a priority as gaming and entertainment. For example, while Cedars-Sinai can technically make its software available in the Meta Quest Store, users would have to go to a section of the store called the App Lab to access it. Software in the App Lab is not marketed traditionally or as easily discoverable via search.

Meta didn’t provide a comment, directing CNBC to a post on Sept. 7, about uses of metaverse technology. The post says: “Training for surgery is just one of the many industries being transformed in ways that are positively impacting lives.”

‘Together in the virtual world’

Doctors at Kettering Health Dayton practice with VR headsets.

Source: Kettering Health Dayton

The technology is also becoming a fixture in many medical schools and residency programs. 

At Kettering Health Dayton, VR recently became a mandatory component of the curriculum for first-year orthopedics residents. In July, the new doctors completed a monthlong “boot camp,” where they carried out clinical services in the mornings and practiced in VR in the afternoons. They now have to complete at least three modules a week in VR with a score of over 70%.

For more senior level residents like Shine, VR training is not yet mandatory, but Kettering Health Dayton is actively working to build it into each level of the program.

“The way I trained in the late 80s, I mean, basically you read the books,” said Dr. Brent Bamberger, the director of the orthopedic surgery residency program at Kettering Health Dayton. “We didn’t have the videos at that time. You may go to a lecture, you may get lucky and have a specimen lab or some type of lab to do it, but you were learning by watching.”

Dr. Reem Daboul, a first-year resident at the hospital, said headsets can’t replicate the physical feeling of a procedure. But she’s found them very useful in important ways. She can already use a headset to walk through the steps of an anterior hip replacement, which many orthopedic surgeons don’t learn until their third year of residency or later.

“Being able to have something help me and see what I’m supposed to be doing and be able to walk through the steps, it’s been super helpful for me,” Daboul said in an interview.

For its orthopedics program, Kettering Health Dayton uses software developed by PrecisionOS, a company that builds VR modules for training surgeons, medical residents and medical device representatives.  PrecisionOS co-founder and CEO, Dr. Danny Goel, said the company has nearly 80 customers across the globe. 

Orthopedics residents at the University of Rochester also use PrecisionOS. Dr. Richard Miller, a retired professor at the university, said the software is “sophisticated” and “very realistic,” especially as a way to learn the steps of a procedure. He finds it so compelling that he’s been actively helping the orthopedics department implement the technology even though he retired three years ago. 

Miller said the VR is a useful way for residents to hone their skills without having to immediately deal with operating room pressures. They can also practice at home.

“I can be at home in my study at night, and they can be in their dorm at night, and we can do a procedure together in the virtual world,” Miller said.

Despite VR’s advantages, Miller said the software has to be able to update frequently to stay current with standards of care, best practices and surgery techniques.

“Next year, they may change the procedure a little bit, now you have other tools and things are a little bit different. Who’s going to change that? Who’s going to bring it up to date?” Miller said.

Those are important questions for quality of care. They’re also important because hospitals generally have to work on tight budgets, and the costs aren’t always clear.

“I can’t get straight answers from anybody, really, as to exactly how much it costs and who does what,” Miller said. “It’s got to be a hurdle.”

PrecisionOS declined to share specific pricing information with CNBC. Goel said costs of using the company’s software vary based on the institution and the partnership.  

Kettering’s Bamberger said that in addition to the software challenges, the hardware is still rather “clunky.” Others in his field also see the limitations.

Dr. Rafael Grossmann, a surgeon at Portsmouth Regional Hospital in New Hampshire, has spent much of his career educating people about health-care applications for emerging technologies like extended reality. 

In 2013, Grossmann became the first person to use the infamous Google Glass during a surgery as a way to stream the procedure, with the patient’s consent, into a room of students. Google had built a lightweight AR device that displayed tiny bits of information on a transparent screen in the user’s field of view. It was first sold to developers and early adopters in 2013 for $1,500, and quickly captured the imagination of tech enthusiasts. 

But Glass never took off. The built-in camera led to fights over privacy, and the product became the butt of jokes on late-night television. 

Ten years later, Grossmann said he now sees a substantial market for the technology, particularly within health care. He said headsets have improved dramatically, even if they’re still bulky and not entirely functional for doctors.

“The interface is better than it was three years ago, but it’s certainly not ideal for really any sort of health-care setting,” Grossmann said.

A gallery assistant wearing an Oculus Quest 2 virtual reality (VR) headset to view the House of Fine Art (HOFA) Metaverse gallery stands in front of digital artwork “Agoria, _{Compend-AI-M}_ 2022 #16” during a preview in Mayfair, London, UK, on Thursday, Nov. 10, 2022. 

Hollie Adams | Bloomberg | Getty Images

A growing area of research

As with all technology in health care, extended reality is going to have to clear regulatory hurdles. 

The U.S. Food and Drug Administration has a small team of researchers that are responsible for carrying out “regulatory science” around the technology. 

Ryan Beams, a physicist at the FDA, conducts this research alongside a team, consulting with a range of experts about emerging AR, VR and mixed reality devices. As a result, Beams said the FDA is able to help establish general best practices for how to test promising devices and bring them to market safely. 

“We can say these are the tests we need done, these are the kinds of ways you should do the tests, and then we can help the companies get through those,” Beams told CNBC. “What you don’t want is a device that potentially could help someone getting delayed because there’s uncertainty about how to go about doing the testing.”

Spiegel of Cedars-Sinai also helped co-found a new medical society called the American Medical Extended Reality Association in late 2022. He said it was created as a way for physicians, clinicians and other health-care professionals to help guide the future of the field. 

The society currently has about 300 paying members, a number Spiegel hopes will reach into the thousands in the coming years. It’s also gearing up to launch its first official peer-reviewed journal called the Journal of Medical Extended Reality. 

“This is not fringe science anymore. This is now mainstream,” Spiegel said. “There’s still a lot of work to do. It’s not like this is a done deal, cake’s not baked, but we’ve seen massive advances on many levels that make this a real science now.”

WATCH: Apple’s VR ‘blows away anything that we’ve ever seen,’ says analyst

Categories
Science

The Case for a Small Universe

The Universe is big, as Douglas Adams would say.

The most distant light we can see is the cosmic microwave background (CMB), which has taken more than 13 billion years to reach us. This marks the edge of the observable universe, and while you might think that means the Universe is 26 billion light-years across, thanks to cosmic expansion it is now closer to 46 billion light-years across. By any measure, this is pretty darn big. But most cosmologists think the Universe is much larger than our observable corner of it. That what we can see is a small part of an unimaginably vast, if not infinite creation. However, a new paper argues that the observable universe is mostly all there is.

In other words, on a cosmic scale, the Universe is quite small.

Remove All Ads on Universe Today

Join our Patreon for as little as $3!

Get the ad-free experience for life

There are several reasons why cosmologists think the Universe is large. One is the distribution of galaxy clusters. If the Universe didn’t extend beyond what we see, the most distant galaxies would feel a gravitational pull toward our region of the cosmos, but not away from us, leading to asymmetrical clustering. Since galaxies cluster at around the same scale throughout the visible universe. In other words, the observable universe is homogenous and isotropic.

A second point is that spacetime is flat. If spacetime weren’t flat, our view of distant galaxies would be distorted, making them appear much larger or smaller than they actually are. Distant galaxies do appear slightly larger due to cosmic expansion, but not in a way that implies an overall curvature to spacetime. Based on the limits of our observations, the flatness of the cosmos implies it is at least 400 times larger than the observable universe.

Inflation would make the CMB temperature uniform. Credit: Nick Strobel

Then there is the fact that the cosmic microwave background is almost a perfect blackbody. There are small fluctuations in its temperature, but it is much more uniform than it should be. To account for this, astronomers have proposed a period of tremendous expansion just after the Big Bang, known as early cosmic inflation. We have not observed any direct evidence of it, but the model solves so many cosmological problems that it’s widely accepted. If the model is accurate, then the Universe is on the order of 1026 times larger than the observable universe.

So given all of this theoretical and observational evidence, how could anyone argue that the Universe is small? It has to do with string theory and the swamplands.

Although string theory is often presented as a physical theory, it’s actually a collection of mathematical methods. It can be used in the development of complex physical models, but it can also just be mathematics for its own sake. One of the problems with connecting the mathematics of string theory to physical models is that the effects would only be seen in the most extreme situations, and we don’t have enough observational data to rule out various models. However, some string theory models appear much more promising than others. For example, some models are compatible with quantum gravity, and others are not. So often theorists will define a “swampland” of theories that aren’t promising.

Most of string theory is in the swampland. Credit: APS/Alan Stonebraker

When you separate the promising theoretical lands from the swamp, what you are left with are theories where early cosmic inflation isn’t an option. Most of the inflationary string theory models are in the swampland. This leads one to ask whether you could construct a model cosmology that matches observation without early inflation. Which brings us to this new study.

One way to get around early cosmic inflation is to look at higher-dimensional structures. Classic general relativity relies upon four physical dimensions, three of space and one of time, or 3+1. Mathematically you could imagine a 3+2 universe or 4+1, where the global structure can be embedded into an effective 3+1 structure. This is a common approach in string theory since it isn’t limited to the standard structure of general relativity. The authors demonstrate that under just the right conditions, you could construct a higher-dimensional structure within string theory that matches observation and avoids the swampland. Based on their toy models, the Universe may only be a hundred or a thousand times larger than the observed universe. Still big, but downright tiny when compared to the early inflation models.

All of this is pretty speculative, but in a way so is early cosmic inflation. If early cosmic inflation is true, we should be able to observe its effect through gravitational waves in the somewhat near future. If that fails, it might be worth looking more closely at string theory models that keep us out of the theoretical swamp.

Reference: Lehners, Jean-Luc and Quintin, Jerome. “A small Universe.” arXiv preprint arXiv:2309.03272 (2023)

Like this:

Like Loading…

Categories
Sport

The Week 2 CFB video games that carry essentially the most CFP impression

Week 2 is here and there are plenty of playoff implications on the line early in the season. Currently, the Pac-12 has a few contenders who are raising their odds of making it, and the Texas-Alabama game carries implications for both sides.

Here are the games and teams that will have the most impact on the College Football Playoff this weekend.

Pac-12’s playoff chances

The Pac-12 has turned heads with its 13-0 start. But the conference still has much to prove to be in the mix come CFP selection day. According to the Allstate Playoff Predictor, there is just a 57% chance that the Pac-12 has a team reach College Football Playoff. To put that into context, both Alabama (63%) and Ohio State (62%) have higher chances to make the CFP than the entire Pac-12.

On the bright side for the Pac-12, its chances have trended upward. Going into the season, Allstate Playoff Predictor put the conference’s chances at getting a CFP representative at 43%. But chances have jumped for USC (21% to 24%), Oregon (9% to 15%) and Washington (2% to 5%).

Notable Pac-12 teams chance to make CFP

Team Preseason Current
USC 21% 24%
Oregon 9% 15%
Utah 8% 8%
Washington 2% 5%
According to Allstate Playoff Predictor

The college football world has its eyes on Tuscaloosa for the eagerly anticipated rematch between Texas and Alabama. Not only does it have the intrigue of Texas looking to avenge last year’s loss, but Saturday night’s game has the biggest impact on the playoff chase. With a win, Alabama’s CFP prospects tick up to 69%, but a loss to the Longhorns would drop the Crimson Tide to only 35%. A win for Texas has much more upside as it would raise the Longhorns’ CFP chances from 17% to 39%.

Editor’s Picks

1 Related

History also suggests the loser of this game is unlikely to be selected to the CFP. Since the four-team playoff began in 2014, only one team has made the CFP with a regular-season loss in nonconference play. That was Ohio State in 2014.

ESPN’s Football Power Index (FPI) gives Alabama an 81% chance to win.

Oklahoma was one of the biggest winners in Week 1, seeing its playoff chances jump from 13% to its current 35%. The Sooners benefited not only from their own dominant win, but also subpar performances by other CFP contenders. A home loss to SMU, a team ranked 46th in FPI, would drop Oklahoma’s CFP chances to 11%.

The Sooners have a favorable schedule. FPI gives Oklahoma at least a 75% chance to win each of its remaining games with the exception of one — Oct. 7 vs. rival Texas. The Sooners have a 57% chance to beat the Longhorns.

Notre Dame has dominated this season, outscoring its two opponents by 92 points. The fast start moved the Fighting Irish from 11% to 18% to reach the CFP.

A win at NC State, ranked 41st in FPI, won’t be a big needle-mover for Notre Dame’s playoff chances, but it will keep it in the mix with a big game against Ohio State looming in two weeks.

Oregon is in a similar boat as Notre Dame because a Week 2 loss to Texas Tech would knock the Ducks to the periphery of the CFP discussion. FPI gives Oregon a 67% chance to win in Lubbock and keep its CFP hopes on course.

Highest team/game leverage for Week 2

Team/game CFP with win CFP with loss
Alabama (vs Texas) 69% 35%
Oklahoma (vs. SMU) 38% 11%
Texas (vs. Alabama) 39% 12%
Notre Dame (vs. NC State) 22% 3%
Oregon (vs. Texas Tech) 22% 3%
According to Allstate Playoff Predictor